专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2014290A3 Utilisation du ténatoprazole pour le traitment du reflux gastro-oesophagien 有权
标题翻译：反流性食管炎的治疗替那拉唑
公开(公告)号：EP2014290A3
公开(公告)日：2009-03-04
申请号：EP08000893.1
申请日：2003-10-21
申请人： Sidem Pharma SA , Mitsubishi Pharma Corporation
发明人： Schutze, François , Charbit, Suzy , Ficheux, Hervé , Homerin, Michel , Taccoen, Alain , Inaba, Yoshio
IPC分类号： A61K31/444 , A61P1/04 , A61P11/00 , A61P11/04 , A61P11/06 , A61P11/14
CPC分类号： A61K31/444
摘要： L'invention concerne une nouvelle indication thérapeutique du ténatoprazole.
Le ténatoprazole, ainsi que ses sels, peut être utilisé dans la fabrication d'un médicament pour le traitement des symptômes atypiques et oesophagiens du reflux gastro-oesophagien, des hémorragies digestives et des dyspepsies.

2. 发明公开

EP1992625A1 Arylamide pyrimidone compounds 审中-公开
标题翻译： Arylamid-Pyrimidon-Verbindungen
公开(公告)号：EP1992625A1
公开(公告)日：2008-11-19
申请号：EP07290626.6
申请日：2007-05-16
申请人： Sanofi-Aventis , Mitsubishi Pharma Corporation
发明人： Lochead, Alistair. , Saady, Mourad. , Veronique, Corinne. , Yaiche, Philippe.
IPC分类号： C07D403/04 , C07D413/14 , A61K31/495 , A61P25/00
CPC分类号： C07D403/04 , A61K9/0019 , A61K9/2018 , A61K9/4858 , C07D413/14 , Y02A50/411
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof:

wherein X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom substituted by a hydrogen atom or a C 1-3 alkyl group, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C 1-6 alkyl group, a hydroxyl group, a C 1-6 alkoxy group, a C 1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 4 or 5-pyrimidine ring or a 4-pyridine ring, the ring being optionally substituted by a C 1-6 alkyl group, a C 1-6 alkoxy group or a halogen atom; R2 represents a benzene ring, a naphthalene ring or a benzyl group ; the rings being optionally substituted by 1 to 4 substituents selected from a C 1-6 alkyl group, C 3-7 cycloalkyl group, a C 3-7 cycloalkyl-C 1-6 alkyl group, a halogen atom, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a hydroxyl group, an heteroaryl group optionally substituted by a C 1-6 alkyl group, C 3-7 cycloalkyl group, a C 3-7 cycloalkyl-C 1-6 alkyl group, C 1-6 alkoxy group optionally substituted by a C 3-5 cycloalkyl group, a C 1-2 perhalogenated alkoxy group, a C 1-6 alkylsulfonyl group, a nitro, a cyano, an amino, a C 1-6 monoalkylamino group or a C 2-12 dialkylamino group, an acetoxy group or an aminosulfonyl group; R3 represents a hydrogen atom, a C 1-6 alkyl group or a halogen atom; R4 represents a hydrogen atom or a C 1-6 alkyl group; R5 represents a hydrogen atom, a C 1-6 alkyl group; R6 represents a hydrogen atom, a C 1-6 alkyl group; R7 represents a hydrogen atom or a C 1-6 alkyl group; n represents 0 to 3 and m represents 1 in the form of a free base or of an addition salt with an acid.
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐或其溶剂合物或其水合物：其中X表示两个氢原子，硫原子，氧原子或C 1-2烷基和氢原子; Z表示键，氧原子，被氢原子或C 1-3烷基取代的氮原子，硫原子，任选被一个或两个选自C 1-6烷基的基团取代的亚甲基，羟基，C 1-6烷氧基，C 1-2全卤代烷基或氨基; R1表示2,4或5-嘧啶环或4-吡啶环，该环任选被C 1-6烷基，C 1-6烷氧基或卤素原子取代; R2表示苯环，萘环或苄基; 该环任选被1至4个选自C 1-6烷基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基，卤素原子，C 1-2 全卤代烷基，C 1-3卤代烷基，羟基，任选被C 1-6烷基取代的杂芳基，C 3-7环烷基，C 3-7环烷基-C 1-6烷基基团，任选被C 3-5环烷基取代的C 1-6烷氧基，C 1-2全卤代烷氧基，C 1-6烷基磺酰基，硝基，氰基，氨基，C 1-6 单烷基氨基或C 2-12二烷基氨基，乙酰氧基或氨基磺酰基; R 3表示氢原子，C 1-6烷基或卤素原子; R 4表示氢原子或C 1-6烷基; R5表示氢原子，C 1-6烷基; R6表示氢原子，C 1-6烷基; R 7表示氢原子或C 1-6烷基; n表示0〜3，m表示1以游离碱或与酸的加成盐形式的1。

3. 发明公开

EP1459743A3 Agent for prophylaxis and treatment of glaucoma 有权
标题翻译：连接到青光眼的预防和治疗
公开(公告)号：EP1459743A3
公开(公告)日：2007-12-26
申请号：EP04014078.2
申请日：1999-08-13
申请人： Senju Pharmaceutical Co., Ltd. , Mitsubishi Pharma Corporation
发明人： Azuma, Mitsuyoshi , Yoshida, Yukuo , Waki, Mitsunori , Uehata, Masayoshi, c/o Mitsubishi Pharma Corp.
IPC分类号： A61K31/00 , A61K31/437 , A61K31/4409 , A61K31/4545 , A61K31/496 , A61K31/551 , A61P27/06
CPC分类号： A61K31/551 , A61K31/00 , A61K31/437 , A61K31/4409 , A61K31/4545 , A61K31/496 , Y10S514/912 , Y10S514/913
摘要： An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I)

wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.

4. 发明公开

EP1842556A1 THERAPEUTIC AGENT FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER 审中-公开
标题翻译：治疗MITTEL GEGEN AUFMERKSAMKEITSDEFIZITEN UNDHYPERAKTIVITÄT
公开(公告)号：EP1842556A1
公开(公告)日：2007-10-10
申请号：EP06711849.7
申请日：2006-01-18
申请人： Mitsubishi Pharma Corporation
发明人： KURIYAMA, Makoto, MITSUBISHI PHARMA CORPORATION
IPC分类号： A61K45/00 , A61K31/5377 , A61P25/14 , A61P43/00 , C07D413/12
CPC分类号： C07D413/12 , A61K31/5377
摘要： A prophylactic and/or therapeutic drug for AD/HD, containing teniloxazine or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, as the active ingredient.
摘要翻译：作为活性成分的含有十一甲氧嗪或其光学异构体或其药学上可接受的盐或其水合物的AD / HD的预防和/或治疗药物。

5. 发明公开

EP1806335A1 METHOD FOR PRODUCING PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE THEREOF 审中-公开
标题翻译：生产苯乙醇胺化合物的方法及其中间体
公开(公告)号：EP1806335A1
公开(公告)日：2007-07-11
申请号：EP05795663.3
申请日：2005-10-19
申请人： Mitsubishi Pharma Corporation
发明人： YASUDA, Nobuyuki,Mitsubishi Pharma Corp,Tokyo Off. , KAJITA, Tsuyoshi
IPC分类号： C07C215/64 , C07C213/04 , C07C213/06 , C07C217/74 , C07B53/00
CPC分类号： C07C213/04 , C07C213/06 , C07C215/64 , C07C2601/14 , C07C217/74
摘要： A novel production method for a phenylethanolamine compound of the following general formula (III):

(wherein R 1 represents a hydrogen atom or a halogen atom; R 2 represents an alkyl group optionally substituted with an alkoxycarbonyl group) ; and a novel production intermediate for it.
摘要翻译：（III）的苯基乙醇胺化合物的新制备方法：（其中R 1表示氢原子或卤素原子; R 2表示任选被烷氧基羰基取代的烷基）; 和一个新的生产中间体。

6. 发明授权

EP1260512B1 NOVEL CYCLIC AMIDE DERIVATIVES 有权
标题翻译：环酰胺衍生物
公开(公告)号：EP1260512B1
公开(公告)日：2007-07-04
申请号：EP01906304.9
申请日：2001-02-26
申请人： Mitsubishi Pharma Corporation
发明人： YAMABE,H. MITSUBISHI-TOKYO PHARM.INC.RESEARCH CEN. , OKUYAMA,M. MITSUBISHI-TOKYO PHARM.INC.RESEARCH CEN , NAKAO,A. MITSUBISHI-TOKYO PHARM.INC.RESEARCH CEN. , OOIZUMI,M. MITSUBISHI-TOKYO PHARM.INC.RESEARCH CEN , SAITO,K. MITSUBISHI-TOKYO PHARM.INC.RESEARCH CEN.
IPC分类号： C07D401/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/048 , C07D495/04 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61P43/00 , A61P25/00 , A61P9/10 , A61P35/00 , A61P1/04 , A61P1/06 , A61P9/06 , A61P9/12
CPC分类号： C07D401/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/04 , C07D495/04
摘要： Novel compounds of the general formula (I) acting as ligands for the binding sites of sigma receptors; and drugs containing the compounds as the active ingredient, wherein X is alkyl, aryl, a heterocyclic group, or the like; Q is -CH2-, -CO-, -O-, -CH(OR7)- (wherein R7 is hydrogen, alkyl, or the like), or the like; n is an integer of 0 to 5; R1 and R2 are each hydrogen, alkyl, or the like; and B is a group represented by the general formula (II) or (III) (wherein R3, R4, R5 and R6 are each hydrogen, halogeno, alkoxy, or the like; m is 1 or 2; and the ring (IV) is an aromatic heterocycle).

7. 发明公开

EP1801108A1 MORPHOLINE COMPOUND 有权
标题翻译：吗啉代替炎症的治疗
公开(公告)号：EP1801108A1
公开(公告)日：2007-06-27
申请号：EP05783689.2
申请日：2005-09-08
申请人： Mitsubishi Pharma Corporation
发明人： TANAKA, Yoshihito, MITSUBISHI PHARMA CORPORATION , TAKEDA, Shuzo, MITSUBISHI PHARMA CORPORATION , HIGASHI, Hidemitsu, MITSUBISHI PHARMA CORPORATION , MATSUURA, Mamoru, MITSUBISHI PHARMA CORPORATION , KOBAYASHI, Fujio, MITSUBISHI PHARMA CORPORATION , HAMADA, Maiko, MITSUBISHI PHARMA CORPORATION , TANAKA, Minoru, MITSUBISHI PHARMA CORPORATION
IPC分类号： C07D265/30 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04 , A61K31/5375 , A61K31/5377 , A61P1/04 , A61P11/02 , A61P11/06 , A61P17/00 , A61P19/02 , A61P27/02 , A61P27/14 , A61P29/00 , A61P37/08 , A61P43/00
CPC分类号： C07D265/30 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04
摘要： A compound represented by the formula (1)

wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

8. 发明公开

EP1792898A1 MOLECULAR CHAPERONE FUNCTION REGULATOR 审中-公开
标题翻译：分子伴侣功能调节器
公开(公告)号：EP1792898A1
公开(公告)日：2007-06-06
申请号：EP05781555.7
申请日：2005-09-01
申请人： Mitsubishi Pharma Corporation
发明人： SUZUKI, Tsuyoshi, c/o MITSUBISHI PHARMA CORP. , FUJII, Akihiro, c/o MITSUBISHI PHARMA CORP. , NAKAMURA, Hideo, c/o MITSUBISHI PHARMA CORP. , YOSHIKAWA, Tsutomu, c/o MITSUBISHI PHARMA CORP.
IPC分类号： C07D239/94 , A61K31/517 , A61P13/08 , A61P15/00 , A61P35/00 , A61P35/02 , A61P43/00
CPC分类号： C07D239/94 , A61K31/517 , C07D401/06 , C07D403/06 , C07D403/12 , C07D405/06 , C07D417/06
摘要： According to the present invention, a molecular chaperone function regulator containing a quinazoline derivative represented by the following formula (I)

wherein each symbol is as defined in Claims, or a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, an optically active form or racemate thereof or a diastereomer mixture thereof as an active ingredient can be provided.
摘要翻译：根据本发明，分子伴侣功能调节剂包含由下式（I）表示的喹唑啉衍生物或其药学上可接受的盐，其水合物或溶剂合物，旋光形式或可以提供其外消旋物或其非对映体混合物作为活性成分。

9. 发明授权

EP1256581B1 PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRIC OR ESOPHAGEAL REGURGITATION 有权
标题翻译：预防或治疗细菌对胃或食管返流
公开(公告)号：EP1256581B1
公开(公告)日：2007-03-28
申请号：EP01902793.7
申请日：2001-02-07
申请人： Mitsubishi Pharma Corporation
发明人： YAMAZAKI, Satoshi, Mitsubishi Pharma Corporation
IPC分类号： C07D453/02 , C07D519/00 , A61K31/439 , A61K31/55 , A61P1/04
CPC分类号： C07D495/04 , A61K31/439 , A61K31/4743
摘要： Compounds represented by the following general formula, pharmaceutically acceptable salts thereof, or hydrates of both exhibit both an excellent enterokinesis-promoting activity and an inhibitory activity against acid secretion and are excellent in safety, thus being useful as preventive or therapeutic agents for gastric or esophageal regurgitation. Formula (1), wherein R?1 and R2¿ are each independently hydrogen or lower alkyl; and A is a substituent selected from the group consisting of 1-azabicyclo[3.2.2]nonyl, 1-azabicyclo[2.2.2]octyl and N-oxides of both.

10. 发明公开

EP1719764A1 METHOD OF ASYMMETRICALLY REDUCING 4- 5-(IMIDAZOL-1-YL)-2-MET HYLBENZOYL -3,5-DIMETHYL-BENZOIC ACID OR ESTER THEREOF 审中-公开
标题翻译： METHOD FOR 4-不对称还原[5-（咪唑-1-基）-2-甲基苯甲酰基] -3,5-二甲基苯甲酸或其酯
公开(公告)号：EP1719764A1
公开(公告)日：2006-11-08
申请号：EP05719508.3
申请日：2005-02-25
申请人： Mitsubishi Pharma Corporation
发明人： USHIO, Hiroyuki, c/o Mitsubishi Pharma Corporation
IPC分类号： C07D233/60 , C07B53/00 , C07B61/00
CPC分类号： C07D233/54
摘要： The invention relates to a method of producing an optically active 4-[hydroxy[5-(imidazol-1-yl)-2-methylphenyl]methyl]-3,5-dimethylbenzoic acid or an ester thereof, which includes reacting 4-[5-(imidazol-1-yl)-2-methylbenzoyl]-3,5-dimethylbenzoic acid or an ester thereof with a silane agent in the presence of a particular zinc compound and an optically active diamine compound.
摘要翻译：本发明涉及在生产的方法的光学活性4- [羟基[5-（咪唑-1-基）-2-甲基苯基]甲基] -3,5-二甲基苯甲酸向或其酯，其包括使4- [ 5-（咪唑-1-基）-2-甲基苯甲酰基] -3,5-二甲基苯甲酸或其酯与在锌化合物的存在下和在特定的光学活性二胺化合物的硅烷试剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式